Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR By: Kahn Swick & Foti, LLC via Business Wire April 26, 2023 at 14:04 PM EDT Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcrr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005880/en/Contacts Kahn Swick & Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR By: Kahn Swick & Foti, LLC via Business Wire April 26, 2023 at 14:04 PM EDT Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcrr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005880/en/Contacts Kahn Swick & Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TCR² Therapeutics Inc. (NasdaqGS: TCRR) to Adaptimmune Therapeutics plc (NasdaqGS: ADAP). Under the terms of the proposed transaction, shareholders of TCR² will receive 1.5117 ADS of Adaptimmune for each share of TCR² that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcrr/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005880/en/
